Al­tria in­vests $2.4 bil­lion for 45% stake in Cana­dian cannabis pro­ducer Cronos

The Guardian (Charlottetown) - - BUSINESS -

TORONTO - Tobacco gi­ant Al­tria Group will in­vest $2.4 bil­lion in Cana­dian cannabis pro­ducer Cronos group for a 45-per-cent own­er­ship stake as the global mar­ket for le­gal pot con­tin­ues to grow. Vir­ginia-based Al­tri, par­ent of the com­pany that makes Marl­boro cig­a­rettes, can also in­vest up to a fur­ther $1.4 bil­lion within four years that would in­crease its own­er­ship stake in Toronto-based Cronos to 55 per cent, un­der the ar­range­ment.

“Al­tria brings scale, ex­per­tise and com­pli­men­tary ca­pa­bil­i­ties... that we be­lieve will en­able us to ex­pand the scope and en­hance the scale of our com­pany,” said Mike Goren­stein, chair­man, pres­i­dent and chief ex­ec­u­tive of­fi­cer of Cronos on a call with an­a­lysts on Fri­day.

As part of the agree­ment, Al­tria will have the right to nom­i­nate four di­rec­tors to the Cronos board, which will be ex­panded to seven mem­bers from five.

“In­vest­ing in Cronos Group as our ex­clu­sive partner in the emerg­ing global cannabis cat­e­gory rep­re­sents an ex­cit­ing new growth op­por­tu­nity for Al­tria,” Howard Wil­lard, Al­tria’s chair­man and chief ex­ec­u­tive of­fi­cer, said Fri­day in a state­ment.

“We be­lieve that Cronos Group’s ex­cel­lent man­age­ment team has built ca­pa­bil­i­ties nec­es­sary to com­pete glob­ally, and we look for­ward to help­ing Cronos Group re­al­ize its sig­nif­i­cant growth po­ten­tial.”

Cronos will re­main a Cana­dian com­pany, head­quar­tered in Toronto, Goren­stein said. Shares of Cronos surged as much as 33 per cent to $18.56 on the Toronto Stock Ex­change from its $13.98 closing price on Thurs­day. It was trad­ing at $17.25 by late morn­ing. The com­pany’s stock on the NAS­DAQ soared by as much as 40 per cent to US$14.58 from its pre­vi­ous close of US$10.45, but was trad­ing at $12.96 by late morn­ing.

Canada on Oct. 17 be­came the sec­ond coun­try in the world to le­gal­ize pot for recre­ational use. Sev­eral U.S. states have le­gal­ized cannabis for med­i­cal or recre­ational use, but pot re­mains il­le­gal un­der fed­eral law.

How­ever, the po­lit­i­cal cli­mate south of the border has been warm­ing up to cannabis. For ex­am­ple, leg­is­la­tion that would al­low for the full le­gal­iza­tion of in­dus­trial hemp in the U.S. and ease re­stric­tions on the cannabis com­pound CBD is work­ing its way through the U.S. leg­isla­tive process.

Dur­ing the U.S. midterm elec­tions, Michi­gan be­came the lat­est state to ap­proval the le­gal­iza­tion or recre­ational cannabis and Utah and Mis­souri ap­proved the drug for med­i­cal pur­poses. Mean­while, the num­ber of coun­tries that have le­gal­ized med­i­cal cannabis con­tin­ues to grow, with South Korea among the lat­est to give the green light.

Al­tria’s in­vest­ment marks the lat­est move by a U.S com­pany in an es­tab­lished in­dus­try to tap the bur­geon­ing Cana­dian cannabis in­dus­try.

In Au­gust, al­co­hol gi­ant Con­stel­la­tion Brands said it would in­vest an ad­di­tional $5 bil­lion in Cana­dian pot pro­ducer Canopy Growth Corp., in­creas­ing its stake to 38 per cent.

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.